DOSSIER · UPDATED 18 JUN 2026

Trevi Therapeutics

Trevi is a clinical-stage biopharmaceutical company focused on the development and commercialization of nalbuphine ER to treat serious neurologically mediated conditions.

trevitherapeutics.com ↗Claim this profile

Founded: 2011
Headcount: 30
Open roles: 0
Last raised: Post Ipo Equity · $173M

SECTION I · THE BRIEF

Inside Trevi Therapeutics

Brief #76488Updated 18 JUN 2026NEW HAVENMEDICAL ORGANIZATIONSPOST IPO EQUITY

Employbl Dossier

Trevi Therapeutics

Trevi is a clinical-stage biopharmaceutical company focused on the development and commercialization of nalbuphine ER to treat serious neurologically mediated conditions.

Founded: 2011
Headcount: 30
Open roles: 0
Last raised: Post Ipo Equity · $173M

Section II · Premium ProfileMembers only

01Engineering interview process at Trevi TherapeuticsLocked
02Tech stack & infrastructure choicesLocked
03Culture & day-to-day work styleLocked
04Why join now vs. 6 months from nowLocked
05Hiring focus & open headcount by teamLocked
06Comp philosophy and band contextLocked

Open Trevi Therapeutics brief Sign in

7-day free trial · $25/mo · cancel anytime

LEADERSHIP

Founders & key people

Jennifer Good

Thomas R. Sciascia

OPEN ROLES

Hiring at Trevi Therapeutics

No open roles listed right now. Check back soon or search all jobs →

FUNDING

Capital raised

Total Amount Raised: $484,100,000